Inozyme Pharma (NASDAQ:INZY) Given “Outperform” Rating at Wedbush

Wedbush reissued their outperform rating on shares of Inozyme Pharma (NASDAQ:INZY) in a report released on Tuesday,RTT News reports. Wedbush currently has a $12.00 price target on the stock, down from their prior price target of $15.00. Wedbush also issued estimates for Inozyme Pharma’s Q4 2024 earnings at ($0.44) EPS, FY2024 earnings at ($1.65) EPS, Q1 2025 earnings at ($0.46) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.34) EPS, Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.45) EPS, FY2026 earnings at ($1.38) EPS and FY2027 earnings at ($0.81) EPS.

Other equities research analysts have also recently issued reports about the company. Stifel Nicolaus assumed coverage on Inozyme Pharma in a report on Thursday, September 12th. They issued a “buy” rating and a $16.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of Inozyme Pharma in a research note on Friday, October 25th. Jefferies Financial Group reissued a “buy” rating and issued a $17.00 price objective (up from $16.00) on shares of Inozyme Pharma in a research note on Tuesday, August 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Inozyme Pharma in a research note on Friday, October 25th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Inozyme Pharma has a consensus rating of “Buy” and an average target price of $15.71.

Inozyme Pharma Trading Down 2.0 %

Shares of NASDAQ:INZY opened at $4.02 on Tuesday. The business’s 50 day moving average price is $5.10 and its 200-day moving average price is $4.92. Inozyme Pharma has a 1 year low of $2.71 and a 1 year high of $7.80. The company has a current ratio of 7.68, a quick ratio of 9.84 and a debt-to-equity ratio of 0.51.

Inozyme Pharma (NASDAQ:INZY) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.05. Research analysts anticipate that Inozyme Pharma will post -1.67 earnings per share for the current year.

Institutional Investors Weigh In On Inozyme Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Deerfield Management Company L.P. Series C purchased a new position in Inozyme Pharma during the 2nd quarter worth $52,000. Meeder Asset Management Inc. purchased a new position in shares of Inozyme Pharma during the second quarter worth about $68,000. Values First Advisors Inc. purchased a new stake in Inozyme Pharma during the 2nd quarter valued at approximately $76,000. SG Americas Securities LLC acquired a new stake in Inozyme Pharma during the 3rd quarter worth approximately $81,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Inozyme Pharma in the 2nd quarter valued at approximately $84,000. Hedge funds and other institutional investors own 88.30% of the company’s stock.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.